Firmagon Hormone Therapy | Treatment of Prostate Cancer

Firmagon is a hormone therapy used in the treatment of advanced prostate cancer. It works by blocking the production of testosterone in the body.

Firmagon FAQ

Image credit: medikament-mexico.com

What are the side effects of Firmagon?

Serious side effects from Firmagon aren’t common, but they can occur. Call your doctor right away if you have serious side effects. Call 911 if your symptoms feel life threatening or if you think you’re having a medical emergency. Impotence (being unable to conceive a child). Disorder of the heart’s electrical activity.

How does Firmagon work?

Firmagon is a man-made form of a protein that reduces the amount of certain hormones in the body, including testosterone. Firmagon injection is used to treat prostate cancer. It works by decreasing the amount of testosterone in the body, which the tumor needs to grow. It is not known if Firmagon is safe or effective in children.

What is degarelix (Firmagon ®)?

Degarelix (Firmagon ®) is a hormonal therapy drug used to treat advanced prostate cancer. t is best to read this information with our information about advanced prostate cancer and hormonal therapies. Your doctor will talk to you about this treatment and its possible side effects before you agree ( consent) to have treatment.

Does Firmagon treat advanced prostate cancer?

The only condition both Firmagon and Lupron Depot are used to treat is advanced prostate cancer. The use of Firmagon and Lupron Depot in treating advanced prostate cancer has been directly compared in a 1-year clinical study. The study involved 620 men with advanced prostate cancer.

What is Firmagon used for?

1. What FIRMAGON is and what it is used for FIRMAGON contains degarelix. Degarelix is a synthetic hormone blocker used in the treatment of prostate cancer and for the treatment of high-risk prostate cancer prior to radiotherapy and in combination with radiotherapy in adult male patients.

Can degarelix (Firmagon®) be used to treat prostate cancer?

Degarelix (Firmagon®) for treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy or as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer (December 2023)